Leap Therapeutics Inc (LPTX)

NASDAQ
Currency in USD
2.4600
-0.0900(-3.53%)
Closed
After Hours
2.5900+0.1300(+5.2846%)
LPTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
Day's Range
2.30002.6600
52 wk Range
1.68004.7900
Key Statistics
Edit
Prev. Close
2.55
Open
2.6
Day's Range
2.3-2.66
52 wk Range
1.68-4.79
Volume
831.05K
Average Volume (3m)
413.85K
1-Year Change
-19.08%
Book Value / Share
1.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LPTX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
9.8233
Upside
+299.32%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Leap Therapeutics Inc Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Compare LPTX to Peers and Sector

Metrics to compare
LPTX
Peers
Sector
Relationship
P/E Ratio
−1.5x−2.3x−0.6x
PEG Ratio
−0.020.100.00
Price/Book
1.9x2.2x2.6x
Price / LTM Sales
-46.5x3.1x
Upside (Analyst Target)
252.9%289.6%50.2%
Fair Value Upside
Unlock14.7%7.5%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.8233
(+299.32% Upside)

Earnings

Latest Release
Aug 11, 2023
EPS / Forecast
-- / -0.088
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Leap Therapeutics (LPTX) Stock Price Today?

The Leap Therapeutics stock price today is 2.46

What Stock Exchange Does Leap Therapeutics Trade On?

Leap Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Leap Therapeutics?

The stock symbol for Leap Therapeutics is "LPTX."

What Is the Leap Therapeutics Market Cap?

As of today, Leap Therapeutics market cap is 94.26M.

What is Leap Therapeutics Earnings Per Share?

The Leap Therapeutics EPS is -1.91.

From a Technical Analysis Perspective, Is LPTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.